Company Description

SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions.

The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), which comprises novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients.

It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021.

The company was incorporated in 2019 and is based in Aliso Viejo, California.

SpyGlass Pharma, Inc.

Country	United States
Founded	2019
IPO Date	Feb 6, 2026
Industry	Biotechnology
Sector	Healthcare
Employees	32
CEO	Patrick Mooney

Contact Details

Address: 27061 Aliso Creek Road, Suite 100 Aliso Viejo, California 92656 United States
Phone	949 284 6904
Website	spyglasspharma.com

Stock Details

Ticker Symbol	SGP
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$16.00
CIK Code	1778922
CUSIP Number	85220G109
ISIN Number	US85220G1094
Employer ID	83-3044245
SIC Code	3841

Key Executives

Name	Position
Patrick Mooney	Chief Executive Officer
Jean-Frederic Viret	Chief Financial Officer
James Dennewill	Chief Operating Officer

Latest SEC Filings

Date	Type	Title
Mar 26, 2026	10-K	Annual Report
Mar 26, 2026	8-K	Current Report
Mar 9, 2026	8-K	Current Report
Feb 17, 2026	SCHEDULE 13G	Filing
Feb 17, 2026	SCHEDULE 13D	Filing
Feb 13, 2026	SCHEDULE 13D	Filing
Feb 13, 2026	SCHEDULE 13D	Filing
Feb 13, 2026	8-K	Current Report
Feb 13, 2026	SCHEDULE 13G	Filing
Feb 10, 2026	SCHEDULE 13D	Filing

View All SEC Filings